Lundbeck
HLUN-B.CO
4,79 €
Share price
-0.06%
Change (1 day)
-16.98%
Change (1 year)
Categories
Lundbeck is a Danish pharmaceutical company that produces various pharmaceutical products and has the indications schizophrenia, depression, Parkinson's disease and sleep disorders.
Revenue for Lundbeck (HLUN-B.CO)
Revenue in 2025 (TTM): €3.07 Billion
According to Lundbeck's latest financial reports the company's current revenue (TTM 
) is €2.87 Billion. In 2024 the company made a revenue of €3.05 Billion an increase over the revenue in the year 2023 that were of €2.61 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Lundbeck from 2009 to 2025
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2025 (TTM) | €3.07 B | 0.76% |
| 2024 | €3.05 B | 16.67% |
| 2023 | €2.61 B | 8.98% |
| 2022 | €2.40 B | 6.81% |
| 2021 | €2.24 B | 0.9% |
| 2020 | €2.22 B | -3.88% |
| 2019 | €2.31 B | -5.98% |
| 2018 | €2.46 B | 11.25% |
| 2017 | €2.21 B | 0.46% |
| 2016 | €2.20 B | 12.22% |
| 2015 | €1.96 B | 1.09% |
| 2014 | €1.94 B | -0.96% |
| 2013 | €1.96 B | 0.4% |
| 2012 | €1.95 B | -14.08% |
| 2011 | €2.27 B | 15.32% |
| 2010 | €1.97 B | 8.91% |
| 2009 | €1.81 B |